Rivaroxaban Tablet, Film Coated
Product Images NDC 72865-321

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 72865-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3 (186d9028 88fd 4703 804c 2e3c98a5b007 02)

A forest plot chart illustrating the fold change and 90% confidence intervals of pharmacokinetic parameters Cmax and AUC for rivaroxaban in various populations: end-stage renal disease on postdialysis, severe, moderate, and mild renal impairment, age groups 75-83 years versus 18-43 years, body weight groups (<=50 kg/70-80 kg and >120 kg/70-80 kg), and moderate and mild hepatic impairment, compared to their respective normal or reference groups.*

FDA Label Image

Image (186d9028 88fd 4703 804c 2e3c98a5b007 03)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals in Cmax and AUC for various interacting drugs relative to rivaroxaban alone. Drugs are grouped by inhibitor or inducer classification, including combined P-gp and CYP3A4 inhibitors and inducers, moderate CYP3A4 inhibitors, and other drugs such as aspirin, atorvastatin, and warfarin.*

FDA Label Image

Fig 9 (186d9028 88fd 4703 804c 2e3c98a5b007 04)

A forest plot comparing the primary efficacy outcome of composite stroke, myocardial infarction, or cardiovascular death between Rivaroxaban and placebo groups. It shows hazard ratios (HR) with 95% confidence intervals for various subgroups including age, sex, region, weight, eGFR, MI history, stroke history, prior heart failure, baseline diabetes, and peripheral artery disease (PAD). The plot visually indicates subgroup-level effects favoring either Rivaroxaban or placebo.*

FDA Label Image

Figure 10 (186d9028 88fd 4703 804c 2e3c98a5b007 05)

A cumulative incidence rate graph comparing Rivaroxaban and Placebo over approximately 1095 days post-randomization. The solid line represents Rivaroxaban with a lower cumulative incidence rate than the dashed Placebo line. The graph includes a table of subjects at risk at several time points and a hazard ratio of 0.74 (95% CI: 0.65-0.86) for Rivaroxaban versus Placebo.*

FDA Label Image

Figure 11 (186d9028 88fd 4703 804c 2e3c98a5b007 06)

A line graph comparing the cumulative incidence rate (%) over days from randomization for two treatment groups: Rivaroxaban (solid line) and Placebo (dashed line). The graph shows lower cumulative incidence for Rivaroxaban than Placebo over approximately 1095 days. A hazard ratio of 0.85 (95% CI: 0.76 to 0.96) is indicated for Rivaroxaban vs Placebo. The number of subjects at risk is provided below the x-axis at various time points for both groups.*

FDA Label Image

Figure 12 (186d9028 88fd 4703 804c 2e3c98a5b007 07)

A forest plot comparing the primary efficacy outcomes of Rivaroxaban versus Placebo across various subgroups including age, sex, weight, eGFR, baseline diabetes, CAD, randomization strata, clopidogrel use at randomization, history of revascularization, and critical limb ischemia categories. The plot shows hazard ratios with confidence intervals, indicating effect sizes and direction for each subgroup.*

FDA Label Image

2.5-180s Counts (2.5 180s Counts)

Rivaroxaban 2.5 mg film-coated tablets label from XL Care Pharmaceuticals Inc. The label includes the NDC 72865-321-18, states 180 tablets, and notes prescription use only. Storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), and caution to keep out of reach of children are also visible. Barcode and 'NO VARNISH' indication appear on the side.*

FDA Label Image

2.5-60s Counts (2.5 60s Counts)

Rivaroxaban 2.5 mg Tablets label from XLCare Pharmaceuticals, Inc. This oral film-coated tablet package contains 60 tablets. The label includes storage instructions, manufacturer information for Ascent Pharmaceuticals, Inc., and a note to dispense the accompanying medication guide to patients. The NDC is 72865-321-60.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure diagram showing the molecular structure of rivaroxaban, the active ingredient in the drug RIVAROXABAN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.